BARBIERI LINDA

Banfi, A., Barbieri, L., Fiandra, L., Salvioni, L., Innocenti, M., Prosperi, D. (2025). Dual-Targeting Strategy to Repurpose Cetuximab with HFn Nanoconjugates for Immunotherapy of Triple-Negative Breast Cancer. Intervento presentato a: Next Gen3ration research - September 18-19, 2025, Genoa, Italy. Dettaglio

Giustra, M., Novati, B., Barbieri, L., Palomer, M., Testa, F., Salvioni, L., et al. (2025). Dual-Modality Detection of Intracellular Nanoparticles via Smart Polymer-Enhanced SERS and Hyperspectral Microscopy Detection. ADVANCED OPTICAL MATERIALS, 13(32) [10.1002/adom.202501881]. Dettaglio

Barbieri, L., Salvioni, L., Banfi, A., Garbujo, S., Fiandra, L., Baioni, C., et al. (2025). Dual-Targeting Strategy to Repurpose Cetuximab with HFn Nanoconjugates for Immunotherapy of Triple-Negative Breast Cancer. ACS APPLIED MATERIALS & INTERFACES, 17(23), 33648-33663 [10.1021/acsami.5c06626]. Dettaglio

Secchi, V., Armanni, A., Barbieri, L., Bruno, A., Colombo, A., Fumagalli, S., et al. (2025). Advanced techniques and nanotechnologies for point-of-care testing. FRONTIERS IN NANOTECHNOLOGY, 6 [10.3389/fnano.2024.1465429]. Dettaglio

Morelli, L., Ochoa, E., Salvioni, L., Davide Giustra, M., De Santes, B., Spena, F., et al. (2024). Microfluidic nanoparticle synthesis for oral solid dosage forms: A step toward clinical transition processes. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 652(5 March 2024) [10.1016/j.ijpharm.2024.123850]. Dettaglio